N/A N=86 HRIPT for Collagen Dressing
Skin Sensitisation
Primary: Skin Sensitization Reaction Using Berger and Bowman Scale — 0; 0; 0; 0 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=68 Human Repeated Insult Patch Test
Dermatitis · Allergy · Contact Allergy
Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
N/A N=81 SPT for Sensitization of Collagen Dressing
Allergy Skin · Allergic Skin Reaction
Primary: Wheal Measurement — 0; 7.91; 0.32 mm
N/A N=22 NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test
Allergy Skin · Allergy · Dermatitis, Allergic Contact
Primary: Wheal Formation — .85; 6.68; .2 mm
N/A N=6 Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Non-small Cell Lung Cancer Stage I
Primary: Examine the T-cell Receptor Profile Changes Induced in the Tumor After SABR
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
Phase 2 N=50 Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Cutaneous Leishmaniasis
Primary: Sensitizing Effects of LtSTA in Leishmania Naive Adults — 8; 22; 9 participants
N/A N=30 Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects
Histological Response of Tissue to Cold
Primary: Biological Tissue Response
N/A N=22 Autologous Regeneration of Tissue (ART) for Wound Healing
Wound of Skin
Primary: Change of Pain on Harvesting of Skin at Donor Site. — 2.6 millimeters
N/A N=2 Feasibility Study: Heavy Water Tissue Labeling Protocol
Skin Laxity
Primary: Rate of Collagen Synthesis — 15.71; 21.22; 36.11; 51.80 percentage of new collagen synthesized
Phase 3 N=39 Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth
Surgery
Primary: Grading Scale for Visual Evaluation of Skin Condition — 0; 0; 0; 0 Scores Ranging (0-7)
Phase 4 N=60 TissueLink Study During Multi-Level Spine Surgery
Low Back Pain
Primary: Hemoglobin Measurement g/dl — 66.2; 102.4 hemoglobin g/dl
N/A N=44 Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts
Gingival Recession
Primary: Differences in Angiogenic Biomarkers — 0.51; .69; 1.04; .67 ng/mL
Phase 1 N=259 Contact Sensitization Potential of 828 Ointment
Healthy Volunteers
Primary: Number of Participants That Exhibited a Score Less Than 1.5 on the Jordan-King Scale — 205 participants
N/A N=24 To Compare Different Soft Tissue Grafts at the Time of Lateral Ridge Augmentation Procedure.
Bone Graft; Complications, Infection or Inflammation · Ridge Deficency · Dental Implant
Primary: Measure Changes Clinically in Crestal Soft Tissue Thickness (in mm) — 1.96; 1.59; 0.33 mm
N/A N=58 Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
Erythema · Sensitisation
Primary: Evidence of Erythema During the Challenge Phase for Omeza Collagen Matrix — 53; 49; 0; 4 Participants
Phase 2 N=48 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Dose Response
Contact Dermatitis
Primary: Diagnostic Performance: Optimal Test Allergen Concentration — 38.1; 47.6; 52.4; 30.8 percentage of participants
N/A N=118 Repeat Insult Patch Test APPENDIX I to HRL Standard Protocol #100
Allergic Sensitization
Primary: Number of Participants That Did Not Have Test Material Induced Clinically Significant Dermal Irritation — 110 Participants
Phase 3 N=23 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
Osteoporosis, Postmenopausal · Osteoporosis · Osteoporosis Vertebral
Primary: Change From Baseline in Mineralizing Surface/Bone Surface (MS/BS) in the Cancellous Envelope at Month 3 — 5.74; 18.66 percentage of MS/BS — p=<0.0001
Phase 2 N=122 Clinical Evaluation of Metal Panel Allergens: Dose Response Study
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
Phase 1 N=59 Cumulative Irritation Potential of 828 Ointment
Healthy Volunteers
Primary: Presence of Cumulative Irritation — 163.0; 109.0; 2073.0 units on a scale
Phase 2 N=24 Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Alveolar Bone Loss
Primary: Bone Regeneration — 79; 63 % bone height
N/A N=48 T Cells and TNF (Tumor Necrosis Factor): The Impact of TNF Blockade
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Measurement of Effector T Helper Type 17 Cells in Peripheral Blood — 466.4; 432; 450; 759.8 spSFC/10^6 — p=0.003
N/A N=135 Evaluation of TNF-α Blockade Effect in Patients With Severe Cutaneous Adverse Drug Reactions
Drug Hypersensitivity
Primary: Skin Healing Time — 13.75; 19; 40.5; 34 days — p=0.01
N/A N=8 Tissue Biomarker for Pegvisomant Action
Acromegaly
Primary: Effect of Pegvisomant on Colon Tissue p53 Expression — 330.57 ng/mL
Phase 4 N=9 Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU
Breast Cancer · Mastectomy
Primary: Complication Rates — 4; 3 Participants
N/A N=63 Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
Graft Versus Host Disease
Primary: CXCL10 in Skin — 273; 41; 7.5 Skin CXCL10 femtograms/micrograms — p=<0.01
N/A N=43 14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin
Cumulative Irritation
Primary: Number of Subjects That Showed no Significant Irritation — 0 participants
N/A N=130 RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
Full-thickness Skin Defects · Degloving Injuries · Crush Injuries
Primary: Incidence of Treatment Area Healing — 30; 34 Treatment Areas — p=.005